Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trialKohei Shitara, Maria Di Bartolomeo, Mario Mandalà et al.|The Lancet|2018Cited by 1.3k
Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial datasetJosef Thaler, Mohamed-Ayman Zawadi, Richard Greil et al.|Annals of Oncology|2015Cited by 4